Computational identification of key genes that may regulate gene expression reprogramming in Alzheimer’s patients

The dementia epidemic is likely to expand worldwide as the aging population continues to grow. A better understanding of the molecular mechanisms that lead to dementia is expected to reveal potentially modifiable risk factors that could contribute to the development of prevention strategies. Alzheimer’s disease is the most prevalent form of dementia. Currently we only partially understand some of the pathophysiological mechanisms that lead to development of the disease in aging individuals. In this study, Switch Miner software was used to identify key switch genes in the brain whose expression may lead to the development of Alzheimer’s disease. The results indicate that switch genes are enriched in pathways involved in the proteasome, oxidative phosphorylation, Parkinson’s disease, Huntington’s disease, Alzheimer’s disease and metabolism in the hippocampus and posterior cingulate cortex. Network analysis identified the krupel like factor 9 (KLF9), potassium channel tetramerization domain 2 (KCTD2), Sp1 transcription factor (SP1) and chromodomain helicase DNA binding protein 1 (CHD1) as key transcriptional regulators of switch genes in the brain of AD patients. These transcriptions factors have been implicated in conditions associated with Alzheimer’s disease, including diabetes, glucocorticoid signaling, stroke, and sleep disorders. The specific pathways affected reveal potential modifiable risk factors by lifestyle changes.

[1]  Wei Ma,et al.  Dexamethasone-induced Krüppel-like factor 9 expression promotes hepatic gluconeogenesis and hyperglycemia. , 2019, The Journal of clinical investigation.

[2]  J. Popp,et al.  High Cortisol and the Risk of Dementia and Alzheimer’s Disease: A Review of the Literature , 2019, Front. Aging Neurosci..

[3]  C. Schwarzer,et al.  Role for Chromatin Remodeling Factor Chd1 in Learning and Memory , 2019, Front. Mol. Neurosci..

[4]  L. Givalois,et al.  Central Role of Glucocorticoid Receptors in Alzheimer’s Disease and Depression , 2018, Front. Neurosci..

[5]  Federica Conte,et al.  Network-Based Approaches to Explore Complex Biological Systems towards Network Medicine , 2018, Genes.

[6]  P. Paci,et al.  Computational identification of specific genes for glioblastoma stem-like cells identity , 2018, Scientific Reports.

[7]  B. Garcia,et al.  TDP-43 Promotes Neurodegeneration by Impairing Chromatin Remodeling , 2017, Current Biology.

[8]  Christopher D. Green,et al.  Impact of Dietary Interventions on Noncoding RNA Networks and mRNAs Encoding Chromatin-Related Factors. , 2017, Cell reports.

[9]  Giulio Pavesi,et al.  SWIM: a computational tool to unveiling crucial nodes in complex biological networks , 2017, Scientific Reports.

[10]  C. A. Frank,et al.  Conserved properties of Drosophila Insomniac link sleep regulation and synaptic function , 2017, bioRxiv.

[11]  L. Vitagliano,et al.  Proteins involved in sleep homeostasis: Biophysical characterization of INC and its partners. , 2016, Biochimie.

[12]  Nick C Fox,et al.  Shared genetic contribution to ischemic stroke and Alzheimer's disease , 2016, Annals of neurology.

[13]  C. Cao,et al.  Transcription factor Sp1 inhibition, memory, and cytokines in a mouse model of Alzheimer's disease. , 2015, American journal of neurodegenerative disease.

[14]  Jennifer Weuve,et al.  Cognitive impairment 18 years before clinical diagnosis of Alzheimer disease dementia , 2015, Neurology.

[15]  Jianguo Xia,et al.  NetworkAnalyst for statistical, visual and network-based meta-analysis of gene expression data , 2015, Nature Protocols.

[16]  M. C. Palumbo,et al.  Integrated Network Analysis Identifies Fight-Club Nodes as a Class of Hubs Encompassing Key Putative Switch Genes That Induce Major Transcriptome Reprogramming during Grapevine Development[W][OPEN] , 2014, Plant Cell.

[17]  Hanspeter Pfister,et al.  UpSet: Visualization of Intersecting Sets , 2014, IEEE Transactions on Visualization and Computer Graphics.

[18]  D. Holtzman,et al.  Sleep and Alzheimer disease pathology—a bidirectional relationship , 2014, Nature Reviews Neurology.

[19]  A. Mauleon,et al.  ATP5H/KCTD2 locus is associated with Alzheimer's disease risk , 2013, Molecular Psychiatry.

[20]  Thanh-Phuong Nguyen,et al.  The Central Role of AMP-Kinase and Energy Homeostasis Impairment in Alzheimer’s Disease: A Multifactor Network Analysis , 2013, PloS one.

[21]  A. Mauleon,et al.  ATP 5 H / KCTD 2 locus is associated with Alzheimer ’ s disease risk , 2013 .

[22]  B. Hyman,et al.  Neuropathological alterations in Alzheimer disease. , 2011, Cold Spring Harbor perspectives in medicine.

[23]  J. Wands,et al.  Alzheimer's Disease is Type 3 Diabetes—Evidence Reviewed , 2008, Journal of diabetes science and technology.

[24]  V. Echeverria,et al.  Transcription factor Sp1 dysregulation in Alzheimer's disease , 2008, Journal of neuroscience research.

[25]  Eric M Reiman,et al.  Altered neuronal gene expression in brain regions differentially affected by Alzheimer's disease: a reference data set. , 2008, Physiological genomics.

[26]  Winnie S. Liang,et al.  Alzheimer's disease is associated with reduced expression of energy metabolism genes in posterior cingulate neurons , 2008, Proceedings of the National Academy of Sciences.

[27]  David Bryant,et al.  DAVID Bioinformatics Resources: expanded annotation database and novel algorithms to better extract biology from large gene lists , 2007, Nucleic Acids Res..

[28]  Eric M Reiman,et al.  Gene expression profiles in anatomically and functionally distinct regions of the normal aged human brain. , 2007, Physiological genomics.

[29]  J. Morris,et al.  Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage alzheimer’s disease , 2001, Journal of Molecular Neuroscience.

[30]  G. Alexander,et al.  Correlations between apolipoprotein E ε4 gene dose and brain-imaging measurements of regional hypometabolism , 2005 .

[31]  Kewei Chen,et al.  Correlations between apolipoprotein E epsilon4 gene dose and brain-imaging measurements of regional hypometabolism. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[32]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.

[33]  Brad T. Sherman,et al.  DAVID: Database for Annotation, Visualization, and Integrated Discovery , 2003, Genome Biology.

[34]  C. Duyckaerts,et al.  A grading system of Alzheimer disease lesions in neocortical areas , 2003, Neurobiology of Aging.

[35]  B. L. Miller,et al.  Atrophy rates of entorhinal cortex in AD and normal aging , 2003, Neurology.

[36]  Brad T. Sherman,et al.  DAVID: Database for Annotation, Visualization, and Integrated Discovery , 2003, Genome Biology.

[37]  J J Mallet,et al.  Regional differences and metabolic changes in normal aging of the human brain: proton MR spectroscopic imaging study. , 2001, AJNR. American journal of neuroradiology.

[38]  J. Mazziotta,et al.  Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[39]  J. Wegiel,et al.  MRI of entorhinal cortex in mild Alzheimer's disease , 1999, The Lancet.

[40]  G. Frisoni,et al.  Hippocampal and entorhinal cortex atrophy in frontotemporal dementia and Alzheimer’s disease , 1999, Neurology.

[41]  C. Jack,et al.  Rate of medial temporal lobe atrophy in typical aging and Alzheimer's disease , 1998, Neurology.

[42]  G. Alexander,et al.  Regional glucose metabolic abnormalities are not the result of atrophy in Alzheimer's disease , 1998, Neurology.

[43]  N. Foster,et al.  Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease , 1997, Annals of neurology.

[44]  M N Rossor,et al.  Atrophy of the Hippocampal Formation in Early Familial Alzheimer's Disease , 1996, Annals of the New York Academy of Sciences.

[45]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[46]  J. Morrison,et al.  Regional distribution of neurofibrillary tangles and senile plaques in the cerebral cortex of elderly patients: a quantitative evaluation of a one-year autopsy population from a geriatric hospital. , 1994, Cerebral cortex.

[47]  K Herholz,et al.  Clinical deterioration in probable Alzheimer's disease correlates with progressive metabolic impairment of association areas. , 1994, Dementia.

[48]  T. Bliss,et al.  A synaptic model of memory: long-term potentiation in the hippocampus , 1993, Nature.

[49]  H. Braak,et al.  The human entorhinal cortex: normal morphology and lamina-specific pathology in various diseases , 1992, Neuroscience Research.

[50]  J. Price,et al.  The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer's disease , 1991, Neurobiology of Aging.

[51]  Gwenn S. Smith,et al.  EARLY MARKER FOR ALZHEIMER'S DISEASE: THE ATROPHIC HIPPOCAMPUS , 1989, The Lancet.

[52]  T. Beach,et al.  Patterns of gliosis in alzheimer's disease and aging cerebrum , 1989, Glia.

[53]  R. Martins,et al.  A4 amyloid protein deposition and the diagnosis of Alzheimer's disease , 1988, Neurology.

[54]  J. Morrison,et al.  Quantitative morphology and regional and laminar distributions of senile plaques in Alzheimer's disease , 1985, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[55]  G. V. Van Hoesen,et al.  Alzheimer's disease: cell-specific pathology isolates the hippocampal formation. , 1984, Science.

[56]  J. A. Hartigan,et al.  A k-means clustering algorithm , 1979 .

[57]  D. Davies,et al.  MYOCARDIAL DISORDERS IN THE ELDERLY. , 1963, Lancet.